Cystic Fibrosis Drugmaker Nivalis Sets Terms For $64M IPO

Nivalis Therapeutics Inc., which is developing a clinical stage treatment for cystic fibrosis, set terms on Wednesday for an initial public offering that could raise as much as $64 million to...

Already a subscriber? Click here to view full article